期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 25, 期 2, 页码 301-306出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2018.09.016
关键词
relapse acute leukemia second transplant
资金
- Public Health Service from the National Cancer Institute [U24CA076518]
- National Heart, Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung and Blood Institute [U10HL069294]
- National Cancer Institute
- Health Resources and Services Administration, Department of Health and Human Services [HHSH250201200016C]
Children with acute leukemia who relapse after hematopoietic cell transplantation (HCT) have few therapeutic options. We studied 251 children and young adults with acute myelogenous or lymphoblastic leukemia who underwent a second HCT for relapse after their first HCT. The median age at second HCT was 11 years, and the median interval between first and second HCT was 17 months. Most of the patients (n = 187; 75%) were in remission, received a myeloablative conditioning regimen (n = 157; 63%), and underwent unrelated donor HCT (n = 230; 92%). The 2-year probability of leukemia free survival (LFS) was 33% after transplantation in patients in remission, compared with 19% after transplantation in patients not in remission (P = .02). The corresponding 8-year probabilities were 24% and 10% (P = .003). A higher rate of relapse contributed to the difference in LFS. The 2-year probability of relapse after transplantation was 42% in patients in remission and 56% in those in relapse (P=.05). The corresponding 8-year probabilities were 49% and 64% (P=.04). These data extend the findings of others showing that patients with a low disease burden are more likely to benefit from a second transplantation. Late relapse led to a 10% decrement in LFS beyond the second year after second HCT. This differs from first HCT, in which most relapses occur within 2 years after HCT. (C) 2018 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据